Literature DB >> 21873736

T cell responses in hepatitis C: the good, the bad and the unconventional.

Paul Klenerman1, Robert Thimme.   

Abstract

Over recent years, it has become increasingly accepted that virus-specific CD4+ and CD8+ T cell responses play a major role in outcome and pathogenesis of hepatitis C virus (HCV) infection. Indeed, while the emergence of strong and multispecific T cell responses may correlate with spontaneous viral clearance, the virus has developed several mechanisms to avoid T cell control in the majority of acutely HCV-infected patients that subsequently develop persistent HCV infection. In this review, we will discuss the current knowledge about the role of cellular immune responses in HCV infection. Specifically, we will emphasise recent new insights into the effector functions of T cells, possible mechanisms of their failure and the host-virus interactions occurring at the site of the disease, the liver.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873736     DOI: 10.1136/gutjnl-2011-300620

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  68 in total

1.  CD40 is required for protective immunity against liver stage Plasmodium infection.

Authors:  Sara A Murray; Isaac Mohar; Jessica L Miller; Katherine J Brempelis; Ashley M Vaughan; Stefan H I Kappe; Ian N Crispe
Journal:  J Immunol       Date:  2015-02-02       Impact factor: 5.422

2.  Statistical linkage analysis of substitutions in patient-derived sequences of genotype 1a hepatitis C virus nonstructural protein 3 exposes targets for immunogen design.

Authors:  Ahmed A Quadeer; Raymond H Y Louie; Karthik Shekhar; Arup K Chakraborty; I-Ming Hsing; Matthew R McKay
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

Review 3.  Living in the liver: hepatic infections.

Authors:  Ulrike Protzer; Mala K Maini; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2012-02-24       Impact factor: 53.106

4.  Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C.

Authors:  K Yanagisawa; S Yue; H J van der Vliet; R Wang; N Alatrakchi; L Golden-Mason; D Schuppan; M J Koziel; H R Rosen; M A Exley
Journal:  J Viral Hepat       Date:  2013-03-11       Impact factor: 3.728

5.  Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.

Authors:  María Q Marín; Patricia Pérez; Karl Ljungberg; Carlos Óscar S Sorzano; Carmen E Gómez; Peter Liljeström; Mariano Esteban; Juan García-Arriaza
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

6.  Murine liver-resident group 1 innate lymphoid cells regulate optimal priming of anti-viral CD8+ T cells.

Authors:  Peter D Krueger; Sowmya Narayanan; Fionna A Surette; Michael G Brown; Sun-Sang J Sung; Young S Hahn
Journal:  J Leukoc Biol       Date:  2016-08-04       Impact factor: 4.962

Review 7.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

8.  Proliferation-competent Tcf1+ CD8 T cells in dysfunctional populations are CD4 T cell help independent.

Authors:  Kristiyan Kanev; Ming Wu; Antar Drews; Patrick Roelli; Christine Wurmser; Madlaina von Hösslin; Dietmar Zehn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-17       Impact factor: 11.205

9.  Acute hepatitis C virus infection in a nurse trainee following a needlestick injury.

Authors:  Renzo Scaggiante; Liliana Chemello; Roberto Rinaldi; Giovanni Battista Bartolucci; Andrea Trevisan
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

10.  Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial).

Authors:  Elena Chernykh; Olga Leplina; Ekaterina Oleynik; Marina Tikhonova; Tamara Tyrinova; Natalia Starostina; Alexandr Ostanin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.